FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
[X] Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended SEPTEMBER 30, 1998 or
[ ] Transition report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the transition period from ______ to ______
1-9731
(COMMISSION FILE NO.)
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 72-0925679
(STATE OR OTHER JURISDICTION OF INCORPORATION OR (I.R.S. EMPLOYER
ORGANIZATION) IDENTIFICATION NO.)
1101 SOUTH CAPITAL OF TEXAS HIGHWAY
BUILDING G - SUITE 200
AUSTIN, TEXAS 78746
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICE) (ZIP CODE)
(512) 347-9640
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
5910 COURTYARD DRIVE #300, AUSTIN TEXAS 78731
(FORMER ADDRESS IF CHANGED SINCE LAST REPORT)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No .
--- ---
As of October 27, 1998 there were 3,563,101 shares of common stock outstanding.
This report consists of 9 pages.
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
TABLE OF CONTENTS
FORM 10-Q
September 30, 1998
PART I - FINANCIAL INFORMATION 3
Item 1. Financial Statements 3
CONSOLIDATED BALANCE SHEETS 3
CONSOLIDATED STATEMENTS OF OPERATIONS 4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY 5
CONSOLIDATED STATEMENTS OF CASH FLOWS 6
SUPPLEMENTAL NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 7
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 7
PART II - OTHER INFORMATION 9
Item 1. Legal Proceedings - none 9
Item 2. Changes in Securities - none 9
Item 3. Defaults Upon Senior Securities - none 9
Item 4. Submission of Matters to a Vote of Security Holders - none 9
Item 5. Other Information - none 9
Item 6. Exhibits and Reports on Form 8-K - none 9
SIGNATURES 9
Page 2 of 9
PART 1- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, December 31,
ASSETS 1998 1997
------------ ------------
Current assets:
Cash and cash equivalents ............................................................. $ 734,137 $ 214,938
Trade and other accounts receivable, net of allowance for doubtful accounts
of $55,345 and $61,318 .......................................................... 1,589,286 2,397,269
Inventories, net ...................................................................... 1,619,920 2,001,123
Income Tax Recoverable ................................................................ 262,808 262,810
Other current assets .................................................................. 114,143 63,861
------------ ------------
Total current assets ................................................................ 4,320,294 4,940,001
Property and equipment, net of accumulated depreciation of $2,679,688 & $2,322,218 ...... 4,007,134 4,195,167
Patent and software development costs, net of accumulated amortization of $438,469
and $422,858 ..................................................................... 80,056 85,667
Goodwill, net of accumulated amortization of $870,568 & $635,476 ........................ 1,759,339 2,025,597
Deferred income taxes, net .............................................................. 458,923 458,923
Other assets ............................................................................ 120,012 127,055
------------ ------------
Total assets ........................................................................ $ 10,745,758 $ 11,832,410
------------ ------------
------------ ------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Revolving credit facilities ........................................................... $ 0 $ 467,135
Current maturities of bonds payable and long-term debt ................................ 136,159 320,328
Current maturities of capital lease obligations ....................................... 5,638 100,371
Accounts payable ...................................................................... 675,403 1,091,550
Income taxes payable .................................................................. 57,620
Accrued liabilities and Other Liabilities ............................................. 626,049 667,172
------------ ------------
Total current liabilities ........................................................... 1,500,869 2,646,556
Bonds payable, and other long-term debt, net of current maturities ...................... 960,752 953,086
Capital lease obligations, net of current portion ....................................... 78,538 92,082
Deferred revenue ........................................................................ 46,693 53,896
------------ ------------
Total liabilities ................................................................... 2,586,852 3,745,620
------------ ------------
Shareholders' equity:
Preferred stock, $1 par value; 2,000,000 shares authorized, none issued ............... - -
Common stock, $.01 par value; 10,000,000 shares authorized;
3,679,216 issued .................................................................. 36,792 36,792
Additional paid-in-capital .............................................................. 8,909,307 8,909,307
Treasury stock, 116,115 shares at cost .................................................. (878,787) (878,787)
Unearned ESOP compensation .............................................................. (49,991) (82,134)
Retained earnings ....................................................................... 141,585 101,612
------------ ------------
Total shareholders' equity .......................................................... 8,158,906 8,086,790
------------ ------------
Total liabilities and shareholders' equity .......................................... $ 10,745,758 $ 11,832,410
------------ ------------
------------ ------------
The accompanying notes are an integral part of the consolidated financial
statements.
Page 3 of 9
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
--------------------------------- --------------------------------
1998 1997 1998 1997
----------- ----------- ----------- -----------
Net sales ...................................... $ 2,323,001 $ 2,825,939 $ 7,597,345 $ 9,529,080
Cost of sales .................................. 1,405,935 1,794,696 4,569,656 6,317,312
----------- ----------- ----------- -----------
Gross profit ................................... 917,066 1,031,243 3,027,689 3,211,768
----------- ----------- ----------- -----------
Selling and marketing .......................... 96,570 161,906 280,062 473,773
General and administrative ..................... 544,282 615,949 1,622,952 1,755,828
Research and development ....................... 68,178 133,130 280,382 256,426
Amortization of goodwill ....................... 31,165 31,800 87,792 92,315
----------- ----------- ----------- -----------
Total expenses ................................. 740,195 942,785 2,271,188 2,578,342
----------- ----------- ----------- -----------
Income from operations ......................... 176,871 88,458 756,501 633,426
Other income (expense):
Interest expense ............................. 20,876 64,664 88,465 176,857
Other ........................................ (8,961) 521 44,184 6,189
----------- ----------- ----------- -----------
Income before income taxes and other charges ... 164,956 23,273 623,852 450,380
Provision for Asset Impairment ................. 0 0 453,529 0
----------- ----------- ----------- -----------
Income (loss) before income taxes .............. 164,956 170,323 450,380
Income taxes (credit) .......................... 105,775 2,407 130,348 177,068
----------- ----------- ----------- -----------
Net income ..................................... $ 59,181 $ 25,680 $ 39,975 $ 273,312
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
Net income per share ........................... $ 0.02 $ 0.01 $ 0.01 $ 0.08
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
Weighted average number of common
and dilutive common equivalent
shares outstanding ........................... 3,563,101 3,563,101 3,563,101 3,563,101
----------- ----------- ----------- -----------
----------- ----------- ----------- -----------
The accompanying notes are an integral part of the consolidated financial
statements.
Page 4 of 9
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
Common Shares Additional
------------------------------ Paid-in Treasury
Number Amount Capital Stock
------------ ------------ ------------ ------------
January 1, 1995 ................. 3,613,035 $ 36,622 $ 8,002,299 $ (363,939)
Exercise of options ............. 17,000 170 67,830
Issuance of warrants ............ 202,000
Maturity and repurchases of
redeemable common stock ....... 627,132
ESOP payments ...................
Treasury stock purchase ......... (65,524) (504,801)
Unrealized securities gain ......
Net income ......................
------------ ------------ ------------ ------------
December 31, 1995 ............... 3,564,511 36,792 8,899,261 (868,740)
Exercise of options
Maturity and repurchases of
redeemable common stock ....... 10,046
ESOP payments ...................
Treasury stock purchase ......... (1,410) (10,046)
Sale of securities
Net income ......................
------------ ------------ ------------ ------------
December 31, 1996 ............... 3,563,101 36,792 8,909,307 (878,786)
Maturity and repurchases of
redeemable common stock
Treasury stock purchase
ESOP payments ...................
Net income ......................
------------ ------------ ------------ ------------
December 31, 1997 ............... 3,563,101 36,792 8,909,307 (878,786)
ESOP payments ...................
Net income ......................
------------ ------------ ------------ ------------
June 30, 1998 ................... 3,563,101 36,792 8,909,307 (878,786)
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
Net Retained
Unearned Unrealized Earnings
ESOP Securities (Accumulated
Compensation Gains Deficit) Total
------------ ---------- ------------ ------------
January 1, 1995 ................. $ (210,705) $ 53,130 $ (1,671,946) $ 5,845,461
Exercise of options ............. 68,000
Issuance of warrants ............ 202,000
Maturity and repurchases of
redeemable common stock ....... 627,132
ESOP payments ................... 42,857 42,857
Treasury stock purchase ......... (504,801)
Unrealized securities gain ...... (53,130) (53,130)
Net income ...................... 1,125,226 1,125,226
------------ ------------ ------------ ------------
December 31, 1995 ............... (167,848) 0 (546,720) 7,352,745
Exercise of options
Maturity and repurchases of
redeemable common stock ....... 10,046
ESOP payments ................... 42,857 42,857
Treasury stock purchase ......... (10,046)
Sale of securities .............. 0
Net income ...................... 616,579 616,579
------------ ------------ ------------ ------------
December 31, 1996 ............... (124,991) 0 69,859 8,012,181
Maturity and repurchases of
redeemable common stock
Treasury stock purchase
ESOP payments ................... 42,857 42,857
Net income ...................... 31,752 31,752
------------ ------------ ------------ ------------
December 31, 1997 ............... (82,134) 0 101,611 8,086,790
ESOP payments ................... 32,142 32,142
Net income ...................... 39,974 39,974
------------ ------------ ------------ ------------
June 30, 1998 ................... (49,992) $ 0 141,585 8,158,906
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
The accompanying notes are an integral part of the consolidated financial
statements.
Page 5 of 9
ARRHYTHMIA RESEARCH TECHNOLOGY, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months Ended September 30,
---------------------------------
1998 1997
----------- -----------
Cash flows from operating activities:
Net Income .............................................................................. $ 39,975 $ 273,312
Provision for Asset Impairment .......................................................... 453,529 0
----------- -----------
Adjusted Net Income ..................................................................... 493,504 273,312
Adjustments to reconcile net income to net cash provided by operating
activities:
Depreciation .......................................................................... 495,839 438,433
Amortization .......................................................................... 117,584 113,719
Deferred Revenue ...................................................................... 0 (29,222)
Changes in assets and liabilities:
(Increase) Decrease in Trade and other accounts receivable, net ....................... 807,983 1,909,550
(Increase) Deposits, prepaid expenses and other current assets ........................ (50,280) (44,382)
(Increase) Decrease in Inventories .................................................... 147,203 310,323
(Decrease) in Accounts payable, accrued liabilities and other current liabilities ..... (606,501) (1,085,999)
Increase in Income taxes payable ...................................................... 57,620 26,617
(Increase) Decrease in Other assets ................................................... (655) 220,779
----------- -----------
Net cash provided by operating activities ................................................. 1,462,297 2,133,130
----------- -----------
Cash flows from investing activities:
Net capital expenditures and fixed asset decrease ....................................... (335,134) (1,267,940)
Deposits on capital equipment, acquisitions and other ................................... 7,695 (250,000)
Patent and software development expenditures ............................................ (17,916) (14,791)
----------- -----------
Net cash used in investing activities ................................................. (345,355) (1,532,731)
----------- -----------
Cash flows from financing activities:
Net repayments of revolving credit facilities ........................................... (467,135) (446,897)
Increase in bonds payable due to amortization ........................................... 36,000 36,000
Reduction of unearned ESOP compensation ................................................. 32,143 32,143
Principal proceeds on long term debt, net ............................................... 0 400,000
Principal payments on long-term debt, net ............................................... (198,751) (281,387)
----------- -----------
Net cash used in financing activities ................................................. (597,743) (260,141)
----------- -----------
Net increase (decrease) in cash and cash equivalents ...................................... 519,199 340,258
Cash and cash equivalents at beginning of period .......................................... 214,938 232,135
----------- -----------
Cash and cash equivalents at end of period ................................................ $ 734,137 $ 572,393
----------- -----------
----------- -----------
NON-CASH INVESTING AND FINANCING ACTIVITIES:
AstroMed acquisition and related note payable $ 300,000
Newmark acquisition and related note payable 200,000
-----------
Total non-cash activity $ 500,000
-----------
-----------
The accompanying notes are an integral part of the consolidated financial
statements.
Page 6 of 9
SUPPLEMENTAL NOTES TO FINANCIAL STATEMENTS
The unaudited interim consolidated financial statements and related notes have
been prepared pursuant to the rules and regulations of the Securities and
Exchange Commission. Accordingly, certain information and footnote disclosures
normally included in financial statements prepared in accordance with generally
accepted accounting principles have been omitted pursuant to such rules and
regulations. The accompanying unaudited interim consolidated financial
statements and related notes should be read in conjunction with the consolidated
financial statements and notes thereto included in the Company's most recent
Form 10-K covering the year ended December 31, 1997.
The information furnished reflects, in the opinion of the management of
Arrhythmia Research Technology, Inc. ("ART"), all adjustments necessary for a
fair presentation of the financial results for the interim period presented.
Interim results are subject to year-end adjustments and audit by
independent certified public accountants.
INVENTORIES:
Inventories consist of the following as of:
September 30, December 31,
1998 1997
---- ----
Raw Materials ............................... $ 273,157 $ 288,255
Work-in-process ............................. 282,794 282,929
Finished goods .............................. 2,093,354 2,250,549
----------- -----------
Total 2,649,305 2,821,733
Allowance for slow-moving inventories ....... (1,029,385) (820,610)
----------- -----------
Total .................................... $ 1,619,920 $ 2,001,123
----------- -----------
----------- -----------
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 1998, the Company had working capital of approximately
$2,788,000. At September 30, 1998, the Company had a $3,500,000 working capital
line of credit with a bank, collateralized by accounts receivable and inventory
of ART and Micron Products Inc. ("Micron"), which bears interest at prime plus
.75% (9.25% at September 30, 1998). The working capital line of credit matures
December 15, 1999 and there was no outstanding balance September 30, 1998. The
Company's lines of credit are its primary source of operating funds and
liquidity.
Capital expenditures during the first nine months of 1998 were
approximately $335,134 compared to $1,267,940 in 1997. Capital expenditures
decreased primarily because Micron completed its wastewater treatment filtration
system in 1997. Capital expenditures are expected to continue to be lower in
1998. Capital expenditures are funded by operating cash flows.
RESULTS OF OPERATIONS
REVENUES for the nine months ended September 30, 1998 decreased 20% when
compared to the nine months ended September 30, 1997. The reason for the reduced
sales is due to an absence of Electrophysiology ("EP") Lab sales this year. EP
Lab sales were $832,747 in the first nine months of 1997 verses $0 this year.
1996 was the final year ART acted as the exclusive distributor for EP products
under its contract with their manufacturer, Prucka Engineering, Inc ("Prucka").
During 1998, ART will receive a 4% commission on net sales of EP systems and
accessories sold anywhere in the world, up to a ceiling of
Page 7 of 9
$10,000,000 in total annual net sales. From January 1, 1999 through December 31,
2002, ART will receive a commission of 3% of net sales of CardioLab systems sold
anywhere in the world, up to a ceiling of $10,000,000 in total net sales. For
revenues attributable to Prucka products that exceed $10,000,000 in any year,
ART will be entitled to receive 25% of the commission rate in effect that
respective year.
Revenues from sales of ECG (Electrocardiograph) sensors decreased by 7.6%
for the nine months ending September 30, 1998 as compared to 1997. The sales mix
for the Company continues with ECG sensors making up a greater proportion of
sales and the related cost of sales.
THIRD QUARTER FIRST NINE MONTHS
1998 % 1997 % 1998 % 1997 %
---- - ---- - ---- - ---- -
Domestic ... $1,130,287 49 $1,662,207 59 $3,920,331 52 $5,843,331 61
Foreign .... 1,192,714 51 1,163,732 41 3,677,014 48 3,685,749 39
---------- --- ---------- --- ---------- --- ---------- ---
Total ...... $2,845,232 100 $2,829,610 100 $7,597,345 100 $9,529,080 100
---------- --- ---------- --- ---------- --- ---------- ---
---------- --- ---------- --- ---------- --- ---------- ---
COST OF SALES decreased 72% for the nine months ended September 30, 1998,
compared to the same period in 1997 because of the absence of EP sales noted
above and the absence of the K-3 Cath Lab sales. K-3 Cath Lab sales in the first
nine months of 1997 were $1,218,767, related cost of sales were $951,800,
compared to $0 sales and cost of sales in the same period of 1998. In our sensor
division, purchases have decreased as this division continues to work on the
silver yield process.
SELLING AND MARKETING expenses decreased 41% compared to the same period in 1997
due to lower sales activity. The primary components of selling and marketing are
salaries and tradeshow expenses. The continuing level of these expenses is
expected to be somewhat lower.
GENERAL AND ADMINISTRATIVE decreased by approximately 7% for the first nine
months of 1998 compared to 1997. The primary components of general and
administrative expenses are salaries and related payroll taxes and benefits,
environmental monitoring expenses, professional fees and insurance costs. Due to
the consolidation of the Austin operation with Micron, (See "Provision for Asset
Impairments" below), general and administrative expenses have decreased.
RESEARCH AND DEVELOPMENT expenses for the first nine months in 1998 increased by
8% compared to the same period in 1997 due to an increase in software
development costs related to Windows software projects for the K-3 Cath Lab and
Predictor I and Predictor II units.
PROVISION FOR ASSET IMPAIRMENTS-In the second quarter of 1998, ART made a
provision of $453,529 to write off goodwill relating to the Astro-Med
acquisition ($172,201), to increase the inventory reserve of the K-3 Cath Lab
inventory ($131,328), to increase the inventory reserve for SAECG inventory
($130,000), and to reflect certain costs associated with reducing and
consolidating the Austin operation with Micron, ($20,000). The per share effect,
after taxes, was a charge of $.08 per share and without the provision, operating
results would have been reported as earnings per share of $.05 for that
quarter..
INCOME TAXES-For the nine months ended September 30, 1998 taxes on income
approximate the statutory rate paid by the Company. The rate is higher than the
federal maximum rate of 31% due to Massachusetts state income tax of 9.5% on
Micron's earnings and Texas franchise taxes.
SAFE HARBOR UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
Forward looking statements made herein are based on current expectations of the
Company that involve a number of risks and uncertainties and should not be
considered as guarantees of future performance. These statements are made under
the Safe Harbor Provisions of the Private Securities Litigation Reform Act of
1995. The factors that could cause actual results to differ materially include:
interruptions or cancellation of existing contracts, impact of competitive
products and pricing, product demand and market acceptance risks, the presence
of competitors with greater financial resources than the Company, product
development and commercialization risks and an inability to arrange additional
debt or equity financing.
Page 8 of 9
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS - NONE
ITEM 2. CHANGES IN SECURITIES - NONE
ITEM 3. DEFAULTS UPON SENIOR SECURITIES - NONE
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - NONE
ITEM 5. OTHER INFORMATION - NONE
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K - NONE
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
------------------------------------
/s/ Anthony A. Cetrone,
President
Chairman of the Board
November 12, 1998
Page 9 of 9